NBIX peer analysis
Neurocrine Biosciences (NBIX) against its competitors: price, today's move, 1-year return and market value side by side.
- NBIX's peers: ACAD (Acadia Pharmaceuticals), AXSM (Axsome Therapeutics), BHVN (Biohaven), GHRS (GH Research), JAZZ (Jazz Pharmaceuticals), NMRA (Neumora Therapeutics), RAPP (Rapport Therapeutics), SUPN (Supernus Pharmaceuticals).
NBIX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals | $17.12 | -2.67% | -25.89% | $2.96B |
| AXSM Axsome Therapeutics | $129.36 | -4.66% | -11.86% | $6.80B |
| BHVN Biohaven | $12.51 | -8.35% | 32.24% | $1.89B |
| GHRS GH Research | $17.53 | -5.55% | 21.91% | $1.20B |
| JAZZ Jazz Pharmaceuticals | $230.62 | -2.47% | 30.97% | $14.80B |
| NMRA Neumora Therapeutics | $0.35 | -5.40% | -86.34% | $65.48M |
| RAPP Rapport Therapeutics | $23.16 | -1.82% | -13.84% | $1.11B |
| SUPN Supernus Pharmaceuticals | $28.00 | -1.23% | -37.64% | $3.30B |
| VNDA Vanda Pharmaceuticals | $3.46 | -5.72% | -32.68% | $209.23M |
| NBIX Neurocrine Biosciences | $150.57 | -3.84% | 9.06% | $15.24B |